A b s t r a c t
immunoglobulin heavy chain isotype expression in B-CLL.
In addition, we demonstrate an association between expression of surface IgD without IgM (IgD-only), a phenotype associated with extensive somatic mutation in normal B cells, [31] [32] [33] and 3 favorable prognostic factors: WBC count less than 30,000/µL (<30 × 10 9 /L), 7 typical morphologic features, [5] [6] [7] and CD38 expression in fewer than 30% of the neoplastic cells, 13, [17] [18] [19] [20] [21] [22] findings that suggest that IgD-only B-CLL may itself be associated with a favorable prognosis.
Materials and Methods

Patient Samples and Morphologic Evaluation
The samples used in the present study comprised peripheral blood and bone marrow aspirate specimens from 76 patients with B-CLL seen in the Special Hematology Laboratory, Hartford Hospital, Hartford, CT. The 76 patients represent a consecutive series of patients with a diagnosis of B-CLL seen between December 1999 and March 2001, for whom WrightGiemsa-stained peripheral smears and complete immunophenotyping data were available. The diagnosis of B-CLL was established on the basis of morphologic and immunophenotypic findings. In all cases, there was an absolute lymphocytosis (>4,500/µL [>4.5 × 10 9 /L]) and monotypic light chain expression. All cases were both CD5+ and CD23+.
Lymphocyte morphologic features were characterized as typical or atypical by one of us (J.A.D.), without knowledge of the immunophenotypic data. Cases designated CLL/ prolymphocytic leukemia (PL) had 11% to 55% prolymphocytes; these cells were medium-sized to large, with a single distinct nucleolus, and moderately pale to lightly basophilic cytoplasm. In the remaining atypical cases, there were 10% or fewer prolymphocytes but more than 15% small, mediumsized, or large cells with irregular or cleaved nuclei and/or cells with plasmacytoid morphologic features (mixed cell CLL) 4,7 ❚Image 1❚, ❚Image 2❚, and ❚Image 3❚.
Flow Cytometric Immunophenotyping
Peripheral blood and bone marrow suspensions were diluted to a concentration of 5 × 10 9 /L with phosphatebuffered saline-azide, 5% albumin (Sigma Chemicals, St Louis, MO). Cell suspensions containing 5 × 10 5 cells were incubated for 15 minutes at room temperature with the appropriate fluorescein isothiocyanate-, phycoerythrin-, and phycoerythrin-Cy5-labeled monoclonal antibodies, and RBCs were lysed using the Immunoprep reagent system (Beckman Coulter, Miami, FL). Cell suspensions for immunoglobulin heavy and light chain studies were prelysed with ammonium chloride (Sigma) and incubated in RPMI (JRH Biosciences, Lenexa, KS) with fetal bovine serum (Hyclone, Logan, UT) at 37°C for 1 hour before staining.
Three-color immunophenotyping data were acquired using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Instrument stability was verified daily with Calibrite beads using FACSComp software (BD Biosciences). Fluorochrome-conjugated monoclonal antibodies routinely used were as follows: CD3, CD5, CD10, CD19, CD20, CD23, CD25, CD33, CD45, CD103, and FMC-7 (Beckman Coulter/ ❚Image 1❚ Typical chronic lymphocytic leukemia. Lymphocytes are small, with relatively round nuclei, condensed chromatin, and scant cytoplasm (Wright-Giemsa, ×1,000).
❚Image 2❚ Atypical chronic lymphocytic leukemia (mixed cell type). Small (top) and medium-sized (lower right) lymphocytes with irregular or cleaved nuclei are admixed with lymphocytes with typical morphologic features (Wright-Giemsa, ×1000).
Immunotech, Miami, FL); CD11c, CD22, CD38, and CD71 (BD Biosciences); IgG, IgA, IgM, and IgD (Caltag, Burlingame, CA); and kappa and lambda (DAKO, Carpinteria, CA). List mode files were analyzed using Cell Quest software (BD Biosciences).
Atypical immunophenotypic characteristics in B-CLL were bright CD20 fluorescence, bright surface immunoglobulin (sIg) light chain fluorescence, or positivity for FMC-7; all cases classified as having atypical immunophenotypic characteristics demonstrated at least 2 of these 3 features. The percentage of CD38+ neoplastic cells was determined as described by Damle et al 13 ; positivity for CD38 was determined by comparison with an isotype control, and the percentage of CD38+ cells among gated CD19+/CD5+ cells was calculated.
Statistical Analysis
Groupwise comparisons of the distributions of quantitative variables (eg, WBC count) were performed using the nonparametric Kruskal-Wallis test. Categoric variables (eg, typical vs atypical morphologic features) were compared using chi-square. All statistical tests were 2-sided. A P value of .05 or less was considered significant.
Results
Distribution of sIg Heavy Chain Isotype Expression in B-CLL
Laboratory, morphologic, and immunophenotypic data for 76 cases of B-CLL are summarized in ❚Table 1❚. Coexpression of IgM and IgD (IgM+/IgD+), a phenotype associated with antigenically naive B cells, 26, 27 was most common, accounting for 55 cases (72%) ❚Figure 1❚. Sixteen cases (21%) were positive for IgD without IgM (IgD-only; Figure 1 ); in normal B cells, the IgD-only phenotype is associated with extensive somatic mutation of IgV genes. [31] [32] [33] The remaining 5 cases, together comprising 7% of all cases, were IgD-( Figure 1 ). Of these 5 cases, 3 were IgM+ and 2 were isotype (class)-switched. Both IgM+ and class-switched normal B cells are memory B cells, with somatically mutated IgV genes. 26, 27 For all subsequent analyses, the 76 cases of B-CLL were divided into 3 groups on the basis of sIg heavy chain isotype expression: IgM+/IgD+, IgD-only, and IgD-.
Laboratory, Morphologic, and Immunophenotypic Correlates of sIg Heavy Chain Isotype Expression
Peripheral WBC count was associated with sIg heavy chain isotype expression ❚Figure 2❚. Mean WBC counts for the IgD-only, IgM+/IgD+, and IgD-groups, respectively, were 21,200/µL (21.2 × 10 9 /L), 42,700/µL (42.7 × 10 9 /L), and 69,100/µL (69.1 × 10 9 /L) (P < .005, Kruskal-Wallis). Cases with a WBC count of more than 30,000/µL (>30 × 10 9 /L) , which is an adverse prognostic factor in B-CLL, 7 also were distributed nonrandomly ❚Figure 3❚; 2 (12%) of IgDonly cases had a WBC count of more than 30,000/µL (>30 × 10 9 /L), compared with 23 (42%) and 4 (80%) of IgM+/IgD+ and IgD-cases, respectively (P = .01, chi-square).
Atypical morphologic features, including CLL/PL and CLL of mixed cell type, were seen in 16 (29%) of IgM+/IgD+ and 3 (60%) of IgD-cases, but none of the IgD-only cases was morphologically atypical (P = .01, chisquare) ❚Figure 4❚. Similarly, atypical immunophenotypic characteristics, including bright expression of CD20 and sIg light chain, as well as positivity for FMC-7, were seen only in IgM+/IgD+ (4 cases [7%]) and IgD-cases (2 cases [40%]); none of the IgD-only cases displayed atypical immunophenotypic characteristics (P = .01, chi-square) ❚Figure 5❚.
The percentage of CD38+ neoplastic cells also was associated with the immunoglobulin heavy chain isotype. The mean percentage of CD38+ cells was lowest in IgD-only cases (2.7%) and highest in IgD-cases (75.4%); IgM+/IgD+ cases displayed an intermediate mean percentage of CD38+ cells (30.0%) (P < .001, Kruskal-Wallis) ❚Figure 6❚. As noted, several groups have shown that CD38 expression in more than 30% of the neoplastic cells is an adverse prognostic factor in B-CLL. 13, [17] [18] [19] [20] [21] [22] Significantly in this regard, none of the IgD-only cases had more than 30% CD38+ cells, compared with 22 (40%) of the IgM+/IgD+ and 5 (100%) of the IgD-cases (P = .0001, chi-square) ❚Figure 7❚.
Finally, only 2 (12%) of the IgD-only cases had 1 or more of the 3 established adverse prognostic factors evaluated 
Discussion
Although B-CLL traditionally has been regarded as a malignant neoplasm of pre-germinal center B cells, studies have demonstrated that a significant proportion of cases have undergone somatic mutation of IgV genes, 11, 12, 34 implying that these cells have transited the germinal center. Moreover, the distinction between germline and mutated IgV gene status has prognostic value; mutated cases are associated with a prolonged clinical course requiring minimal therapy, while germline cases are associated with a more aggressive course and greater requirements for treatment. [13] [14] [15] [16] [17] During © American Society of Clinical Pathologists normal B-cell maturation within the germinal center, antigenically naïve IgM/IgD-bearing B cells may become IgM+ memory cells and/or, in a process known as isotype (class) switching, may become IgG-or IgA-bearing cells. 26, 27 In both normal B-cell development [28] [29] [30] and in B-CLL, 12 somatic mutation of IgV genes is more prevalent and extensive among isotype-switched cells.
These findings prompted us to compare immunoglobulin heavy chain expression in B-CLL with a number of laboratory, morphologic, and immunophenotypic features, some of which are established prognostic factors. The data demonstrate that WBC count, atypical morphologic features, atypical immunophenotypic characteristics, and CD38 positivity are distributed nonrandomly with regard to heavy chain isotype expression, suggesting that heavy chain expression may reflect some of the biologic diversity in B-CLL. Moreover, we report that IgD-only B-CLL, which accounts for 21% of cases (16/76) in this series, is associated with low WBC count, typical morphologic features, and CD38 positivity in fewer than 30% of the neoplastic cells, all of which are favorable prognostic factors in B-CLL. [5] [6] [7] 13, [17] [18] [19] [20] [21] [22] This observation suggests the possibility that IgD-only B-CLL may itself be associated with a favorable prognosis. Prolonged clinical follow-up of these cases will be required to test this proposal directly, however.
Data in the literature regarding IgD-only B-CLL are sparse, although in one series of 540 cases of B-CLL, of which 6.6% were IgD-only, sIg heavy chain expression was not associated with survival. 35 However, 3 groups have suggested that the IgM-only phenotype is associated with a worse prognosis or greater propensity for progressive disease compared with IgM+/IgD+ cases. [36] [37] [38] In this regard, our finding that IgD-B-CLL (including IgM-only B-CLL) is associated with high WBC count, atypical morphologic features, and CD38 positivity in more than 30% of cells, all of which are adverse prognostic factors, is perhaps noteworthy.
The relationship between CD38 expression and immunoglobulin heavy chain expression is intriguing and may indirectly reflect normal B-cell maturation. In the mantle zone of normal human lymphoid follicles, naïve or virgin B cells with germline IgV genes express surface IgM and IgD, without CD38. 39 Within the germinal center, wherein the IgV genes undergo somatic mutation, there may be loss of IgD and acquisition of CD38. 39 Post-germinal center memory B cells are heterogeneous with respect to heavy chain expression and include IgM+/IgD+, IgM-only, and class-switched cells 26, 27 that lack expression of CD38. 39 A subset of germinal center and peripheral blood B cells expressing IgD without IgM has been identified. [31] [32] [33] These memory B cells are remarkable for a relatively high load of IgV gene mutations. Our finding that none of the 16 B-CLL cases with an IgD-only phenotype was CD38+ is noteworthy in this regard, as the absence of CD38 expression in these cases may reflect a memory B-cell phenotype. Experiments to test this hypothesis are in progress.
Our findings provide a possible explanation for the controversy over the correlation between CD38 expression and somatic mutation of IgV genes. Damle and colleagues 13, 18 reported a strong association between CD38 positivity in more than 30% of cells and absence of sIg mutations. Indeed, several other groups have likewise observed an association, but have stressed that it is imperfect and that CD38 expression does not consistently predict mutational status. [15] [16] [17] 22, 23, 25 However, Damle et al 13 specifically excluded isotype-switched cases from their analysis. As has been demonstrated by others, 12 isotype-switched cases of B-CLL are more likely to have somatic mutations than IgM+/IgD+ cases, yet our data suggest that IgD-cases (ie, cases with a "memory" B-cell phenotype, including isotypeswitched cases) are also more likely to express CD38. IgD-B-CLL, therefore, might yield discordant results when considering mutational status vs CD38 expression (ie, they may be both somatically mutated and CD38+). Because Damle et al 13 restricted their analysis to a more phenotypically homogeneous group of cases, the association between IgV gene mutational status and CD38 expression in their series may have been stronger than that seen by others. If this hypothesis were correct, then CD38 expression might, in fact, remain a potential surrogate marker for mutational status, but only among IgM+/IgD+ cases. We have shown that WBC count, atypical morphologic features, atypical immunophenotypic characteristics, and CD38 expression are distributed nonrandomly among IgM+/IgD+, IgD-only, and IgD-B-CLL. In addition, we report that the subset of IgD-only B-CLL is associated with 3 established favorable prognostic factors: low WBC count, typical morphologic features, and CD38 expression in fewer than 30% of cells, suggesting the possibility that IgD-only B-CLL may itself be associated with a favorable prognosis. Flow cytometric evaluation of sIg heavy chain expression may have clinical usefulness in B-CLL, and further study is warranted. 
